Table I.
Administered UCMSC dose and pretreatment characteristics of the type 2 diabetes patients.
| Pretreatment characteristic | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Age (years) | Duration (months) | First dose (×106cells/kg) | Second dose (×106cells/kg) | Interval (days) | Follow-up (months) | Insulin-free period (months) | BMI (kg/m2) | HbA1c (%) | Fasting C-peptide (ng/ml) | Cmax (ng/ml) | Insulin dose (IU/kg/day) | Diabetic complications | |
| 1 | 47 | 4 | 0.88 | 0.85 | 16 | 44 | 43 | 24.25 | 10.1 | 1.08 | 5.07 | 0.225 | None | |
| 2 | 42 | 36 | 0.95 | 0.94 | 14 | 36 | RI | 24.31 | 8.9 | 1.26 | 4.03 | 0.296 | None | |
| 3 | 51 | 84 | 0.86 | 0.87 | 17 | 35 | RI | 23.60 | 7.4 | 0.56 | 1.32 | 0.779 | None | |
| 4 | 27 | 12 | 0.90 | 0.87 | 16 | 32 | 29 | 23.24 | 6.3 | 0.91 | 3.61 | 0.405 | None | |
| 5 | 32 | 48 | 0.81 | 0.79 | 14 | 28 | 25 | 22.50 | 9.8 | 1.42 | 5.69 | 0.267 | None | |
| 6 | 44 | 72 | 0.88 | 0.90 | 15 | 24 | RI | 24.10 | 8.8 | 0.96 | 2.16 | 0.619 | None | |
| Averagea | 40.5±3.76 | 42.7±13.02 | 0.88±0.02 | 0.87±0.02 | 15.3±0.49 | 33.2±2.82 | 23.7±0.29 | 8.55±0.59 | 1.03±0.12 | 3.65±0.68 | 0.43±0.09 | None | ||
c
Results are expressed as the mean ± standard error. RI, reduced insulin requirement; UCMSC, umbilical cord mesenchymal stem cell; BMI, body mass index; HbA1c, glycated hemoglobin; Cmax, peak concentration (C-peptide).